Therapy Optimization in Population Dynamics Models

Cell subpopulations dealt with in the preceding chapter were the result of compartmentalizing the model. In this chapter we focus on growth of cancer cells and the associated vascular system and interactions with the immune system. Therefore, though the variables will still describe the amount of cells of different type, there will be no flux from one type to another. We start with introduction of standard models of population dynamics, with exponential, Gompertzian, and logistic growth. The difference between stochastic and deterministic approach to model population size is explained, a point often misinterpreted in various sources. Then, the angiogenic aspects of cancer growth are discussed, followed by several models of cancer growth including vascularization. Consequently, the problem of optimization of antiangiogenic and combined therapies is analyzed. Finally, models of gene and immunotherapy in cancer treatments are briefly reviewed. In addition to discussion of optimal treatment protocols, the focus of this chapter is on the formal, system engineering-based analysis of dynamical properties of systems under investigation, such as stability and controllability.

[1]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[2]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[3]  Laurence Zitvogel,et al.  Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors , 2014, Oncoimmunology.

[4]  Urszula Ledzewicz,et al.  Minimizing Tumor Volume for a Mathematical Model of Anti-Angiogenesis with Linear Pharmacokinetics , 2010 .

[5]  Antoni Ribas,et al.  Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.

[6]  D. Earn,et al.  Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models , 2011, Bulletin of mathematical biology.

[7]  T. Malthus Essay on the Principle of Population , 2001 .

[8]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Marek Bodnar,et al.  Time delay in necrotic core formation. , 2005, Mathematical biosciences and engineering : MBE.

[10]  L. Wein,et al.  Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.

[11]  Pamela F. Jones,et al.  The foundations of a unified approach to mathematical modelling of angiogenesis , 2009 .

[12]  S. Lakshminarayanan,et al.  Optimization of chemotherapy and immunotherapy: In silico analysis using pharmacokinetic–pharmacodynamic and tumor growth models , 2013 .

[13]  Andrzej Świerniak Comparison of six models of antiangiogenic therapy , 2009 .

[14]  J. Folkman,et al.  Angiogenesis Inhibitors Generated by Tumors , 1995, Molecular medicine.

[15]  Urszula Ledzewicz,et al.  Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.

[16]  J. Klamka Controllability of dynamical systems , 1991, Mathematica Applicanda.

[17]  Andrzej Swierniak,et al.  Comparison of Simple Models of Periodic Protocols for Combined Anticancer Therapy , 2013, Comput. Math. Methods Medicine.

[18]  Eugenia Corvera Poiré,et al.  Tumor Angiogenesis and Vascular Patterning: A Mathematical Model , 2011, PloS one.

[19]  D A Lauffenburger,et al.  Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis. , 1991, Journal of theoretical biology.

[20]  J. Denekamp,et al.  Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy , 1993 .

[21]  Alberto Gandolfi,et al.  Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.

[22]  H. Schättler,et al.  On optimal delivery of combination therapy for tumors. , 2009, Mathematical biosciences.

[23]  Jerzy Klamka,et al.  Local Controllability of Models of Combined Anticancer Therapy with Delays in Control , 2014 .

[24]  Jaroslaw Smieja,et al.  Singularity of Optimal Antiangiogenic Strategies - Exception or Rule , 2010 .

[25]  Andrzej Swierniak,et al.  Periodic control in antiangiogenic and combined anticancer therapies , 2010, PSYCO.

[26]  Robert Preissner,et al.  Theoretical Modeling Techniques and Their Impact on Tumor Immunology , 2010, Clinical & developmental immunology.

[27]  Peteris Daugulis,et al.  Hopf point analysis for angiogenesis models , 2003 .

[28]  Dmitry I. Gabrilovich,et al.  Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer , 2013, Cancer Immunology, Immunotherapy.

[29]  Yuri Kogan,et al.  Critical-point analysis for three-variable cancer angiogenesis models. , 2005, Mathematical biosciences and engineering : MBE.

[30]  Yuri Kogan,et al.  Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics , 2008, Cancer Immunology, Immunotherapy.

[31]  Thomas B. L. Kirkwood,et al.  Deciphering death: a commentary on Gompertz (1825) ‘On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies’ , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[32]  Urszula Ledzewicz,et al.  On the Optimality of Singular Controls for a Class of Mathematical Models for Tumor Anti-Angiogenesis , 2009 .

[33]  Michael Kalos,et al.  T cell-based gene therapy of cancer. , 2013, Translational research : the journal of laboratory and clinical medicine.

[34]  Urszula Ledzewicz,et al.  AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..

[35]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[36]  Z. Agur,et al.  A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth , 2004, Angiogenesis.

[37]  M Gyllenberg,et al.  Quiescence as an explanation of Gompertzian tumor growth. , 1989, Growth, development, and aging : GDA.

[38]  Urszula Foryś,et al.  Analysis of the Hopf bifurcation for the family of angiogenesis models , 2011 .

[39]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[40]  G. Yancopoulos,et al.  The angiopoietins: Yin and Yang in angiogenesis. , 1999, Current topics in microbiology and immunology.

[41]  N. Weidner Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.

[42]  A K LAIRD,et al.  Cell fractionation of normal and malignant tissues. , 1954, Experimental cell research.

[43]  J. Pinilla-Ibarz,et al.  Developing strategies in the immunotherapy of leukemias. , 2013, Cancer control : journal of the Moffitt Cancer Center.

[44]  Alberto Gandolfi,et al.  A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. , 2008, Mathematical medicine and biology : a journal of the IMA.

[45]  M. Chaplain,et al.  Continuous and discrete mathematical models of tumor-induced angiogenesis , 1998, Bulletin of mathematical biology.

[46]  M J Plank,et al.  A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. , 2003, Mathematical medicine and biology : a journal of the IMA.

[47]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[48]  B. Teicher,et al.  Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions , 2005 .

[49]  Jerzy Klamka,et al.  Controllability of a model of combined anticancer therapy , 2013 .

[50]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[51]  Judah Folkman,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994 .

[52]  Andrzej Swierniak,et al.  Control Theory Approach to Cancer Chemotherapy: Benefiting from Phase Dependence and Overcoming Drug Resistance , 2006 .

[53]  D. Yu,et al.  Advances in Combination of Antiangiogenic Agents Targeting VEGF‐binding and Conventional Chemotherapy and Radiation for Cancer Treatment , 2010, Journal of the Chinese Medical Association : JCMA.

[54]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[55]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[56]  Urszula Ledzewicz,et al.  Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. , 2010, Mathematical medicine and biology : a journal of the IMA.

[57]  Judah Folkman,et al.  Angiogenesis in vitro , 1980, Nature.

[58]  Helen M. Byrne,et al.  20 Mathematical modelling of angiogenesis and vascular adaptation1 , 2005 .

[59]  Shay Soker,et al.  VEGF/VPF: The angiogenesis factor found? , 1993, Current Biology.

[60]  H. Othmer,et al.  Mathematical modeling of tumor-induced angiogenesis , 2004, Journal of mathematical biology.

[61]  R. Kerbel Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[62]  M. Essand,et al.  Genetically engineered T cells for the treatment of cancer , 2013, Journal of internal medicine.

[63]  A. Świerniak,et al.  Direct and indirect control of cancer populations , 2008 .

[64]  F Castiglione,et al.  Cancer immunotherapy, mathematical modeling and optimal control. , 2007, Journal of theoretical biology.

[65]  David J. Waxman,et al.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment , 2008, Molecular Cancer Therapeutics.

[66]  Dirk Hasenclever,et al.  Modelling Lymphoma Therapy and Outcome , 2014, Bulletin of mathematical biology.

[67]  Laurence Zitvogel,et al.  Immunotherapy and the concept of a clinical cure. , 2013, European journal of cancer.

[68]  J. Bischoff,et al.  Approaches to studying cell adhesion molecules in angiogenesis. , 1995, Trends in cell biology.

[69]  Jung-Han Kimn,et al.  Optimization of Virotherapy for Cancer , 2010, Bulletin of mathematical biology.

[70]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[71]  Xiaoming Zheng,et al.  A Cell-based Model of Endothelial Cell Migration, Proliferation and Maturation During Corneal Angiogenesis , 2010, Bulletin of mathematical biology.

[72]  R. Kerbel A cancer therapy resistant to resistance , 1997, Nature.

[73]  Yi Jiang,et al.  A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. , 2007, Biophysical journal.

[74]  Urszula Foryś,et al.  ANGIOGENESIS MODEL WITH CARRYING CAPACITY DEPENDING ON VESSEL DENSITY , 2009 .

[75]  Alberto Gandolfi,et al.  Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular "pruning". , 2010, Journal of theoretical biology.

[76]  Jonathan Dushoff,et al.  Multi-Stability and Multi-Instability Phenomena in a Mathematical Model of Tumor-Immune-Virus Interactions , 2011, Bulletin of mathematical biology.

[77]  M. Malisoff,et al.  Constructions of Strict Lyapunov Functions , 2009 .

[78]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[79]  S. McDougall,et al.  Mathematical modelling of flow through vascular networks: Implications for tumour-induced angiogenesis and chemotherapy strategies , 2002, Bulletin of mathematical biology.